Effectiveness of a single 3-mg rasburicase dose for the management of hyperuricemia in patients with hematological malignancies

Bone Marrow Transplantation

Volumn 46, Issue 6, 2011, Pages 800-805

  Trifilio, S M ^a   Pi, J ^a   Zook, J ^a   Golf, M ^a   Coyle, K ^a   Greenberg, D ^a   Newman, D ^a   Koslosky, M ^a   Mehta, J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

hematological malignancy; hyperuricemia; rasburicase

Indexed keywords

CREATININE; RASBURICASE; URIC ACID;

ACUTE LEUKEMIA; ADULT; AGED; ALKALINIZATION; ARTICLE; BLOOD SAMPLING; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG EFFICACY; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYDRATION; HYPERURICEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MYELOMA; NONHODGKIN LYMPHOMA; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; TUMOR LYSIS SYNDROME; URIC ACID BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; GOUT SUPPRESSANTS; HEMATOLOGIC NEOPLASMS; HUMANS; HYPERURICEMIA; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; URATE OXIDASE; URIC ACID; YOUNG ADULT;

EID: 79958115135     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.212     Document Type: Article

References (15)

1. Davidson MB, Thakkar S, Hix JK, Bhandarkar ND, Wong A, Schreiber MJ. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am JMed 2004; 116: 546-554. (Pubitemid 38452647)
2. Tiu RV, Mountantonakis SE, Dunbar AJ, Schreiber Jr MJ. Tumor lysis syndrome. Semin Thromb Hemost 2007; 33: 397-407. (Pubitemid 46878112)
3. Wu XW, Lee CC, Muzny DM, Caskey CT. Urate oxidase: primary structure and evolutionary implications. Proc Natl Acad Sci USA 1989; 86: 9412-9416. (Pubitemid 20010436)
4. Leach M, Parsons RM, Reilly JT, Winfield DA. Efficacy of urate oxidase (uricozyme) in tumour lysis induced urate nephropathy. Clin Lab Haematol 1998; 20: 169-172. (Pubitemid 28313577)
5. Goldman SC, Holcenberg JS, Finklestein JZ, Hutchinson R, Kreissman S, Johnson FL et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001; 97: 2998-3003.
6. Rényi I, Bárdi E, Udvardi E, Kovács G, Bartyik K, Kajtár P et al. Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin's lymphoma. Pathol Oncol Res 2007; 13: 57-62. (Pubitemid 46883548)
7. Pui CH, Mahmoud HH, Wiley JM, Woods GM, Leverger G, Camitta B et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 2001; 19: 697-704. (Pubitemid 32119083)
8. Pui CH, Jeha S, Irwin D, Camitta B. Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. Leukemia 2001; 15: 1505-1509.
9. Coiffier B, Mounier N, Bologna S, Fermé C, Tilly H, Sonet A et al. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol 2003; 21: 4402-4406. (Pubitemid 46621817)
10. Trifilio S, Gordon L, Singhal S, Tallman M, Evens A, Rashid K et al. Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia. Bone Marrow Transplant 2006; 37: 997-1001.
11. Hummel M, Reiter S, Adam K, Hehlmann R, Buchheidt D. Effective treatment and prophylaxis of hyperuricemia and impaired renal function in tumor lysis syndrome with low doses of rasburicase. Eur J Haematol 2008; 80: 331-336. (Pubitemid 351347575)
12. Hutcherson DA, Gammon DC, Bhatt MS, Faneuf M. Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy. Pharmacotherapy 2006; 26: 242-247. (Pubitemid 43201871)
13. Coiffier B, Altman A, Pui CH, Younes A. Cairo guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 2008; 26: 2767-2778.
14. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004; 127: 3-11. (Pubitemid 39331101)
15. http://products.sanofi-aventis.us/elitek/elitek.html (accessed 4 February 2010).